Author

S. Shenker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

L. Cadzow· 2 shared A. A. Wylie· 1 shared A. E. Dodson· 1 shared A. Hohmann· 1 shared C. Bullock· 1 shared C. Calnan· 1 shared C. Dugopolski· 1 shared C. Middleton· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

L. Cadzow

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell Lines

A. E. Dodson, S. Shenker, P. Sullivan, C. Middleton, M. McGuire, E. Chipumuro, Y. Mishina, E. Tobin, L. Cadzow, A. A. Wylie, D. Sangurdekar

This study predicts HRD in 1,332 cancer and 84 non-cancer cell lines using CHORD and HRDsum, finding BRCA1/2 mutations and epigenetic silencing as key predictors.

Cancer Research Communications · Dec 6, 2024Peer-reviewedCancer Biology

Rational design of a SOCS1-edited tumor infiltrating lymphocyte therapy for solid tumors using CRISPR/Cas9 screens

M. R. Schlabach, S. Lin, Z. Collester, C. Wrockage, S. Shenker, C. Calnan, T. Xu, H. Gannon, L. Williams, F. Thompson, P. Dunbar, R. LaMothe, T. E. Garrett, N. Colletti, A. Hohmann, , M. J. Benson

This study uses CRISPR/Cas9 screens to identify SOCS1 as a target for enhancing T cell therapy, leading to the development of an engineered TIL therapy with improved anti-tumor function.

bioRxiv · Sep 5, 2023 · PreprintImmunology